Alasmari, M.S.; Alqahtani, F.; Alasmari, F.; Alsultan, A.
Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment. Pharmaceutics 2024, 16, 1540.
https://doi.org/10.3390/pharmaceutics16121540
AMA Style
Alasmari MS, Alqahtani F, Alasmari F, Alsultan A.
Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment. Pharmaceutics. 2024; 16(12):1540.
https://doi.org/10.3390/pharmaceutics16121540
Chicago/Turabian Style
Alasmari, Mohammed S., Faleh Alqahtani, Fawaz Alasmari, and Abdullah Alsultan.
2024. "Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment" Pharmaceutics 16, no. 12: 1540.
https://doi.org/10.3390/pharmaceutics16121540
APA Style
Alasmari, M. S., Alqahtani, F., Alasmari, F., & Alsultan, A.
(2024). Model-Based Dose Selection of a Sphingosine-1-Phosphate Modulator, Etrasimod, in Patients with Various Degrees of Hepatic Impairment. Pharmaceutics, 16(12), 1540.
https://doi.org/10.3390/pharmaceutics16121540